Literature DB >> 7526455

Acute reversible ataxo-myoclonic encephalopathy with flecainide therapy.

J Ghika1, J J Goy, C Naegeli, F Regli.   

Abstract

A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia developed an acute reversible encephalopathy within 15 days of initiation of flecainide. The clinical picture was characterized by visual hallucinations, agitation, anxiety, but no disorientation, and a severe cerebello-myoclonic syndrome with total inability to stand up and walk, which was fully reversible on discontinuing the medication.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7526455

Source DB:  PubMed          Journal:  Schweiz Arch Neurol Psychiatr (1985)        ISSN: 0258-7661


  4 in total

Review 1.  Safety of flecainide.

Authors:  Juan Tamargo; Alessandro Capucci; Philippe Mabo
Journal:  Drug Saf       Date:  2012-04-01       Impact factor: 5.606

Review 2.  Drug-induced movement disorders.

Authors:  F J Jiménez-Jiménez; P J García-Ruiz; J A Molina
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

Review 3.  Drug-induced myoclonus: frequency, mechanisms and management.

Authors:  Félix Javier Jiménez-Jiménez; Inmaculada Puertas; María de Toledo-Heras
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

4.  When potion becomes poison! A case report of flecainide toxicity.

Authors:  S Bajaj; M S Tullu; Zah Khan; M Agrawal
Journal:  J Postgrad Med       Date:  2017 Oct-Dec       Impact factor: 1.476

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.